Abstract
MicroRNAs (miRNAs) and promoter hypermethylation are vital epigenetic mechanisms for transcriptional inactivation of tumor suppressor. IRX1 is a newly identified tumor suppressor gene and hypermethylation involves the decreased expression in gastric cancer. However, the microRNA regulatory mechanism on IRX1 expression is still unclear. In this study, we report an IRX1-targeting miRNA-544, which directly targets 3'-UTR of IRX1 gene by luciferase reporter assay. miR-544 suppresses the protein expression of IRX1 gene by Western blot and immunocytochemistry. Ectopic expression of miR-544 promotes cell proliferation and cell cycle progression significantly in vitro on gastric cancer cells. The study suggests that miR-544 is an oncogenic microRNA in gastric cancer. Over expression of miR-544 contributes to the inactivation and low-expression of IRX1 in gastric cancer. These findings are helpful for clarifying the molecular mechanisms involved in gastric carcinogenesis and indicate that miR-544 is a key regulator in switching cell cycle on or off. miR-544 may be a potential molecular target in miRNA-based strategy on gastric cancer.
Keywords: Gastric cancer, IRX1, MiR-544, Oncogenic microRNA
Anti-Cancer Agents in Medicinal Chemistry
Title:Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer
Volume: 13 Issue: 2
Author(s): Qiaoming Zhi, Xiaobo Guo, Lei Guo, Rongjuan Zhang, Jinling Jiang, Jun Ji, Jianian Zhang, Jun Zhang, Xuehua Chen, Qu Cai, jianfang Li, Bingya Liu, Zhenggang Zhu and Yingyan Yu
Affiliation:
Keywords: Gastric cancer, IRX1, MiR-544, Oncogenic microRNA
Abstract: MicroRNAs (miRNAs) and promoter hypermethylation are vital epigenetic mechanisms for transcriptional inactivation of tumor suppressor. IRX1 is a newly identified tumor suppressor gene and hypermethylation involves the decreased expression in gastric cancer. However, the microRNA regulatory mechanism on IRX1 expression is still unclear. In this study, we report an IRX1-targeting miRNA-544, which directly targets 3'-UTR of IRX1 gene by luciferase reporter assay. miR-544 suppresses the protein expression of IRX1 gene by Western blot and immunocytochemistry. Ectopic expression of miR-544 promotes cell proliferation and cell cycle progression significantly in vitro on gastric cancer cells. The study suggests that miR-544 is an oncogenic microRNA in gastric cancer. Over expression of miR-544 contributes to the inactivation and low-expression of IRX1 in gastric cancer. These findings are helpful for clarifying the molecular mechanisms involved in gastric carcinogenesis and indicate that miR-544 is a key regulator in switching cell cycle on or off. miR-544 may be a potential molecular target in miRNA-based strategy on gastric cancer.
Export Options
About this article
Cite this article as:
Zhi Qiaoming, Guo Xiaobo, Guo Lei, Zhang Rongjuan, Jiang Jinling, Ji Jun, Zhang Jianian, Zhang Jun, Chen Xuehua, Cai Qu, Li jianfang, Liu Bingya, Zhu Zhenggang and Yu Yingyan, Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020013
DOI https://dx.doi.org/10.2174/1871520611313020013 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Natural Flora and Anticancer Regime: Milestones and Roadmap
Anti-Cancer Agents in Medicinal Chemistry PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology Identification of Key mRNAs, miRNAs, and mRNA-miRNA Network Involved in Papillary Thyroid Carcinoma
Current Bioinformatics Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dysregulation of Lysyl Oxidases Expression in Diabetic Nephropathy and Renal Cell Carcinoma
Current Drug Targets Thyroid Function and Obesity: From Mechanisms to the Benefits of Levothyroxine in Obese Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology